## 3 Results  
Of the 175 patients with known T2 DM who were evaluated for liver fibrosis in the Gastroenterology Department, 24 (13.7%) were excluded due to unreliable pSWE measurements. Compared to the reliable group (n--151), the unreliable group was older (62.3 \(\pm\) 12.8 vs. 51.6 \(\pm\) 13.5, _p_--0.874) and mostly comprised men (47.5% vs. 45.1%, _p_--0.478), but this was not statistically significant. The BMI of the unreliable group was higher (32.4 \(\pm\) 2.8 vs. 29.3 \(\pm\) 2.5, _p_--0.147), but the difference did not reach statistical significance. The rate of agreement between the NFS score and the pSWE values, or the proportion of patients for whom both tests yielded the same results, was met in 134 patients (88.7%). These patients were recruited for the final evaluation (Table 1). Based on these values, the patients were divided into two groups (the F1/F2 group, defined as having both an NFS score \(<\) 0.65 and a pSWE value \(<\) 1.7 m/s, and the F3/F4 group, defined as having both an NFS score \(>\) 0.65 and a pSWE value \(>\) 1.7 m/s). A comparison of the clinical and biochemical characteristics of the two groups of patients is shown in Table 2. \begin{table}
\begin{tabular}{c c} \hline \hline
**Parameters** & **Value** \\ \hline Female (\%) & 56.25 \\ \hline Male (\%) & 43.75 \\ \hline Age (years) & 49.39 \(\pm\) 8.19 \\ \hline Waist circumference (cm) & 92.28 \(\pm\) 10.08 \\ \hline BMI (kg/m\({}^{2}\)) & 29.33 \(\pm\) 2.51 \\ \hline Hypertension (\%) & 73.85 \\ \hline MS (\%) & 74 \\ \hline Cholesterol (mg/dL) & 227.42 \(\pm\) 65.2 \\ \hline HDL-C (mg/dL) & 36.21 \(\pm\) 6.05 \\ \hline LDL-C (mg/dL) & 106.3 \(\pm\) 47.2 \\ \hline Serum triglycerides (mg/dL) & 195.65 \(\pm\) 58.91 \\ \hline AST (U/L) & 83.98 \(\pm\) 18.11 \\ \hline ALT (U/L) & 86.41 \(\pm\) 30.41 \\ \hline GGT (U/L) & 107.02 \(\pm\) 52.17 \\ \hline Albumin (g/dL) & 3.7 \(\pm\) 0.58 \\ \hline INR & 1.03 \(\pm\) 0.14 \\ \hline Duration of T2 DM (years) & 7.7 (3.4–11.5) \\ \hline Insulin use (\%) & 62.25 \\ \hline Serum glucose (g/dL) & 114.45 \(\pm\) 19.88 \\ \hline HbA1c (\%) & 6.55 (5.1–9.2) \\ \hline HOMA-IR & 3.06 \(\pm\) 0.54 \\ \hline NFS & 0.29 (\(-\)1.5–2.4) \\ \hline FIB-4 & 2.74 (0.66–9.41) \\ \hline APRI & 1.02 \(\pm\) 0.43 \\ \hline pSWE (m/s) & 1.3 \(\pm\) 0.45 \\ \hline \hline \end{tabular} BMI—body mass index; MS—metabolic syndrome; HDL–C—high-density cholesterol; LDL–—low-density cholesterol; AST—aspartate amino transferase; ALT—alanine amino transferase; GGT—glutamyltransferase; INR—internal normalized ratio; HbA1c—glycoslated hemoglobin; HOMA-IR—homeostatic model assessment of insulin resistance; NFS—NAFLD fibrosis score; FIB-4—Fibrosis 4; APRI—AST-to-platelet ratio; pSWE—point shear-wave elastography.  
\end{table} 
Table 1: Baseline characteristics of the 134 patients with diabetes. The prevalence of liver steatosis in our study group was 85.8% (n--115). We found that 37.3% (n--50) of patients had S1 steatosis, 44% (n--59) had S2 steatosis, and 17.9% (n--25) had S3 steatosis. The prevalence of severe fibrosis (F3/F4) based on pSWE and NFS scores was 18.7% (n--25), while 81.3% (n--109) of patients were classified as not having severe fibrosis (F1/F2). Patients with severe fibrosis were more likely to be older and have a higher waist circumference. Furthermore, they were more likely to have metabolic syndrome and low levels of albumin. Moreover, patients with severe fibrosis had greater levels of serum triglycerides, AST, ALT, GGT, serum glucose, and HbA1c, and a higher HOMA-IR. Regarding the noninvasive markers of liver fibrosis, patients with severe fibrosis had a statistically significant increase in FIB-4, APRI, and NFS scores. Table 3 shows the diagnostic performances and accuracies of the parameters predicting the presence of F3/F4 in patients with T2 DM. GGT, age, BMI, HOMA index, FIB-4, APRI, NFS, and HbA1C were significant predictors for the diagnosis of the F3/F4 group.